Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 8/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008319 | 0.93 | — | — | |
| Sulfuric Acid SCHEMBL22367546 | 0.85 | POLB (0.34) | EPHX1CA2DPP4DPP7DPP8 | |
| SCHEMBL30251693 | 0.83 | — | — | |
| SCHEMBL4028231 | 0.81 | HPGD (0.38) | GAAHPGDCA12CA1CA2 | |
| SCHEMBL18639814 | 0.79 | HPGD (0.37) | GAAHPGDCA12CA1CA2 | |
| SCHEMBL74963 | 0.79 | HPGD (0.37) | GAAHPGDCA12CA1CA2 | |
| SCHEMBL2907315 | 0.77 | F2 (0.41) | — | |
| SCHEMBL10808899 | 0.77 | CHRM2 (0.46) | GAAHPGD | |
| SCHEMBL5329524 | 0.77 | HPGD (0.36) | GAAHPGDCA12CA1CA2 | |
| SCHEMBL4772277 | 0.77 | HPGD (0.37) | GAAHPGDCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138951-A1 | TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION | JNANA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-09 | — | — | US | disclosed |
| US-20220306674-A1 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-29 | — | — | US | disclosed |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | NEUROCRINE BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| US-8207156-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-06-26 | — | — | US | disclosed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| EP-1910302-A1 | CARBONYL SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 RECEPTOR MODULATORS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009687-A1 | CARBONYL SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306674-A1 | (2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | EPHX1 4773/4885GAA 168/4885HPGD 3334/4885 |
| US-11033539-B2 | Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases | CHRM2, CHRM4, CHRM1 | EPHX1 1532/4885GAA 1102/4885HPGD 3294/4885 |
| US-20260138951-A1 | TREATING PKU WITH SPIRO-SUBSTITUTED AND OTHER PIPERIDINE INHIBITORS OF SLC6A19 FUNCTION | SLC6A19, SLC6A9, SLC2A9 | EPHX1 1611/4885GAA 361/4885HPGD 842/4885 |
| US-20180325887-A1 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM1, CHRM2, CHRM4 | EPHX1 2016/4885GAA 1918/4885HPGD 3221/4885 |
| US-12410208-B2 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | EPHX1 4773/4885GAA 168/4885HPGD 3334/4885 |
| US-20210338653-A1 | N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES | CHRM2, CHRM1, CHRM4 | EPHX1 3120/4885GAA 1965/4885HPGD 3487/4885 |
| US-20070021398-A1 | Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | PIR, SYMPK, P2RX5 | EPHX1 3499/4885GAA 2158/4885HPGD 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.